Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | APP | P05067 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL71899 | 1.00 | CYP3A4 (0.37) | CYP3A4TDP1ALDH1A1TP53TAAR1 | |
| Hydrochloric Acid SCHEMBL3286109 | 1.00 | CYP3A4 (0.37) | CYP3A4TDP1ALDH1A1TP53TAAR1 | |
| Hydrochloric Acid SCHEMBL28977209 | 0.98 | CYP3A4 (0.36) | CYP3A4TDP1ALDH1A1TP53TAAR1 | |
| Hydrochloric Acid SCHEMBL21357686 | 0.98 | CYP3A4 (0.36) | CYP3A4TDP1ALDH1A1TP53TAAR1 | |
| Hydrochloric Acid SCHEMBL557242 | 0.98 | CYP3A4 (0.36) | CYP3A4TDP1ALDH1A1TP53TAAR1 | |
| SCHEMBL41543 | 0.98 | CYP3A4 (0.39) | CYP3A4TDP1ALDH1A1TP53TAAR1 | |
| Water SCHEMBL28537381 | 0.96 | CYP3A4 (0.37) | CYP3A4TDP1ALDH1A1TP53TAAR1 | |
| Hydrogen Peroxide SCHEMBL3706944 | 0.94 | CYP3A4 (0.36) | CYP3A4TDP1ALDH1A1TP53TAAR1 | |
| Carbon Tetrachloride SCHEMBL29029110 | 0.91 | ALDH1A1 (0.33) | CYP3A4TDP1ALDH1A1TP53 | |
| SCHEMBL5803242 | 0.83 | CYP3A4 (0.49) | CYP3A4HSD17B10MEN1MAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 855 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114624197-B | Detection method for blood concentration of small molecule drug | 西湖大学 | 2024-09-03 | — | — | CN | claimed |
| WO-2023098087-A1 | METHOD FOR MEASURING PLASMA CONCENTRATION OF SMALL MOLECULE DRUG | 西湖大学 | 2023-06-08 | — | — | WO | claimed |
| US-20230157577-A1 | NON-INVASIVE WEARABLE SENSOR DEVICE FOR DETECTING BIOMARKERS IN SECRETION | CHULALONGKORN UNIVERSITY (TH) | 2023-05-25 | — | — | US | claimed |
| CN-114624197-A | Method for detecting blood concentration of small molecule drug | 西湖大学 | 2022-06-14 | — | — | CN | claimed |
| EP-3791186-A1 | ANTIGEN BIOMARKER OF MICROSATELLITE INSTABILITY | Instituto de Patologia e Imunologia da Universidad do Porto (IPATIMUP) (PT) | 2021-03-17 | — | — | EP | claimed |
| US-12624081-B2 | Tn-MUC1 chimeric antigen receptor (CAR) T cell therapy | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2026-05-12 | — | — | US | disclosed |
| US-12612431-B2 | Cyclic compounds for treating cancer | UNIVERSITY OF SOUTH FLORIDA (US) | 2026-04-28 | — | — | US | disclosed |
| US-12600715-B2 | Soluble guanylate cyclate activators for treating systemic sclerosis | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2026-04-14 | — | — | US | disclosed |
| US-12570761-B2 | Anti-CEACAM5 antibodies and uses thereof | SANOFI (FR) | 2026-03-10 | — | — | US | disclosed |
| US-12501901-B2 | Endophytic microbes for growth promotion of crop plants and suppression of aggressive invasive plant species | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2025-12-23 | — | — | US | disclosed |
| EP-4611758-A1 | SOLUBLE GUANYLATE CYCLASE ACTIVATORS FOR TREATING SYSTEMIC SCLEROSIS | Boehringer Ingelheim International GmbH (DE) | 2025-09-10 | — | — | EP | disclosed |
| US-20250228960-A1 | METHODS FOR INCREASING EFFICACY OF FOLR1 CANCER THERAPY | IMMUNOGEN, INC. (US) | 2025-07-17 | — | — | US | disclosed |
| EP-0378621-A1 | DIAGNOSTICS AND THERAPY FOR RHEUMATOID ARTHRITIS | GAY, Steffen (US) | 1990-07-25 | — | — | EP | disclosed |
| WO-1990006757-A1 | GRAFTING GENETICALLY MODIFIED CELLS TO TREAT DISEASES OF THE CENTRAL NERVOUS SYSTEM | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1990-06-28 | — | — | WO | disclosed |
| WO-1989011285-A1 | DIAGNOSTICS AND THERAPY FOR RHEUMATOID ARTHRITIS | GAY STEFFEN (US) | 1989-11-30 | — | — | WO | disclosed |
| EP-0304481-A4 | MONOCLONAL ANTIBODIES PRODUCED AGAINST GLOMERULAR PROTEOGLYCANS. | UNIV ROCKEFELLER (US) | 1989-07-11 | — | — | EP | disclosed |
| EP-0304481-A1 | MONOCLONAL ANTIBODIES PRODUCED AGAINST GLOMERULAR PROTEOGLYCANS | THE ROCKEFELLER UNIVERSITY (US) | 1989-03-01 | — | — | EP | disclosed |
| US-4770995-A | TUMOR CELLS | NEW YORK BLOOD CENTER, INC (US) | 1988-09-13 | — | — | US | disclosed |
| WO-1988006620-A1 | MONOCLONAL ANTIBODIES PRODUCED AGAINST GLOMERULAR PROTEOGLYCANS | THE ROCKEFELLER UNIVERSITY (US) | 1988-09-07 | — | — | WO | disclosed |
| US-4628027-A | Vitro diagnostic methods using monoclonal antibodies against connective tissue proteins | MOLECULAR ENGINEERING ASSOCIATES, LTD. (US) | 1986-12-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12570761-B2 | Anti-CEACAM5 antibodies and uses thereof | TNFRSF9, IGSF11, FCGR2A | CYP3A4 4658/4885TDP1 665/4885ALDH1A1 4112/4885 |
| US-12600715-B2 | Soluble guanylate cyclate activators for treating systemic sclerosis | GUCY1A1, GUCY1B2, GUCY1B1 | CYP3A4 3160/4885TDP1 1327/4885ALDH1A1 2275/4885 |
| US-12612431-B2 | Cyclic compounds for treating cancer | EGFR, ERBB2, ERBB4 | CYP3A4 4321/4885TDP1 4077/4885ALDH1A1 4760/4885 |
| US-12624081-B2 | Tn-MUC1 chimeric antigen receptor (CAR) T cell therapy | MUC1, CD274, IL2RA | CYP3A4 4740/4885TDP1 1145/4885ALDH1A1 3755/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.